Phase I study of concurrent carboplatin and radiotherapy in previously untreated patients with stage III and IV head and neck cancer

Head & Neck ◽  
1991 ◽  
Vol 13 (3) ◽  
pp. 217-222 ◽  
Author(s):  
David Osoba ◽  
Albino D. Flores ◽  
John H. Hay ◽  
Frances Wong ◽  
Maureen Maher
Keyword(s):  
Head And Neck Cancer ◽  
Phase I ◽  
Head And Neck ◽  
Neck Cancer ◽  
Phase I Study ◽  
Stage Iii

Phase I Study of S-1 plus Nedaplatin in Patients with Advanced/Recurrent Head and Neck Cancer

Chemotherapy ◽  
2010 ◽  
Vol 56 (6) ◽  
pp. 453-458 ◽  
Author(s):  
Yasunao Kogashiwa ◽  
Kohichi Yamauchi ◽  
Hiroshi Nagafuji ◽  
Takehiro Matsuda ◽  
Toshihito Tsubosaka ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Phase I ◽  
Head And Neck ◽  
Neck Cancer ◽  
Phase I Study ◽  
Recurrent Head

A phase I study of cisplatin, tirapazamine and accelerated re-irradiation in unresectable recurrent head and neck cancer

2004 ◽  
Vol 22 (14_suppl) ◽  
pp. 5511-5511 ◽  
Author(s):  
E. E. W. Cohen ◽  
D. Rosine ◽  
E. Loh ◽  
D. J. Haraf ◽  
E. E. Vokes ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Phase I ◽  
Head And Neck ◽  
Neck Cancer ◽  
Phase I Study ◽  
Recurrent Head

Phase I study of panitumumab + chemoradiotherapy (CRT) for head and neck cancer (HNC)

2008 ◽  
Vol 26 (15_suppl) ◽  
pp. 6007-6007 ◽  
Author(s):  
L. J. Wirth ◽  
M. R. Posner ◽  
R. B. Tishler ◽  
R. I. Haddad ◽  
J. R. Clark ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Phase I ◽  
Head And Neck ◽  
Neck Cancer ◽  
Phase I Study

Phase I study of ridaforolimus with cetuximab for patients with advanced non-small cell lung cancer (NSCLC), colorectal cancer, and head and neck cancer.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. 8075-8075
Author(s):  
Angela Marie Taber ◽  
Humera Khurshid ◽  
Kimberly Perez ◽  
Ariel E. Birnbaum ◽  
Adam J. Olszewski ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Colon Cancer ◽  
Head And Neck Cancer ◽  
Phase I ◽  
Head And Neck ◽  
Dose Level ◽  
Neck Cancer ◽  
Phase I Study ◽  
Mtor Inhibitor ◽  
Egfr Antibody

8075 Background: mTOR inhibition may overcome PI3K/AKT pathway mediated resistance to anti-EGFR therapy. We performed a phase I study to determine the dose-limiting toxicity (DLT) of ridaforolimus, an investigational oral mTOR inhibitor, in combination with the anti-EGFR antibody cetuximab. Methods: Patients with advanced NSCLC, colorectal cancer, and head and neck cancer that progressed after at least 1 prior regimen for metastatic disease were eligible. ECOG performance status 0-1. Patients with previously treated brain metastases that were stable for >3 months were eligible. Wild-type K-RAS was required in colon cancer. All patients received cetuximab 400 mg/m2 week 1 followed by 250 mg/m2 weekly. Three dose levels of ridaforolimus were planned: 20mg, 30mg, and 40mg daily, 5 days each week, on a 28-day cycle. Results: 12 patients were entered with NSCLC (n=7), colon cancer (n=4), and head and neck cancer (n=1). The median age was 58 (42-69). The median number of prior regimens for metastatic disease, by disease type, was NSCLC (n=3), colorectal (n=4), head & neck (n=4). Three patients completed the first dose level without DLT. Two of 3 patients at dose level 2 had dose-limiting mucositis. The first dose level was then expanded with six additional patients with NSCLC without any further dose-limiting toxicities. The recommended phase II dose of ridaforolimus is 20 mg daily, 5 days a week, in combination with cetuximab. Response and prolonged stable disease was demonstrated in NSCLC. Conclusions: The DLT of the combination of ridaforolimus and cetuximab is mucositis. The activity observed in heavily pretreated patients with NSCLC suggests that the combination of an mTOR inhibitor with an EGFR antibody merits further investigation in NSCLC. Clinical trial information: NCT01212627.

Phase I study of weekly docetaxel and cisplatin arterial infusion for recurrent head and neck cancer

Head & Neck ◽  
2011 ◽  
Vol 34 (11) ◽  
pp. 1634-1639
Author(s):  
Tatsuya Nakamura ◽  
Nobukazu Fuwa ◽  
Kanako Takayama ◽  
Haruo Inokuchi ◽  
Takuya Tomoda ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Phase I ◽  
Head And Neck ◽  
Neck Cancer ◽  
Phase I Study ◽  
Arterial Infusion ◽  
Weekly Docetaxel ◽  
Recurrent Head

scholarly journals Phase I Study of Oral S-1 and Concurrent Radiotherapy in Patients with Head and Neck Cancer

2010 ◽  
Vol 78 (3) ◽  
pp. S450-S451
Author(s):  
K. Nakata ◽  
M. Someya ◽  
M. Takagi ◽  
J. Hayashi ◽  
K. Miura ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Phase I ◽  
Head And Neck ◽  
Neck Cancer ◽  
Phase I Study ◽  
Concurrent Radiotherapy

scholarly journals Phase I study of Caelyx (doxorubicin HCL, pegylated liposomal) in recurrent or metastatic head and neck cancer

2000 ◽  
Vol 11 (3) ◽  
pp. 339-342 ◽  
Author(s):  
F. Caponigro ◽  
P. Cornelia ◽  
A. Budillon ◽  
J. Bryce ◽  
A. Avallone ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Phase I ◽  
Head And Neck ◽  
Neck Cancer ◽  
Phase I Study

Phase I Study of Concomitant Chemoradiotherapy with Irinotecan, 5-FU., and Hydroxyurea for Patients with Advanced and/or Recurrent Head and Neck Cancer

2005 ◽  
Vol 11 (2) ◽  
pp. 140-146 ◽  
Author(s):  
Joseph K. Salama ◽  
Daniel J. Haraf ◽  
Kerstin Stenson ◽  
Michael T. Milano ◽  
Mary Ellyn Witt ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Phase I ◽  
Head And Neck ◽  
Neck Cancer ◽  
Phase I Study ◽  
Concomitant Chemoradiotherapy ◽  
Recurrent Head
Sign in / Sign up

Export Citation Format

Share Document